Investigational drug · Phase 2
VX-01
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "VX-01"
First trial start
2025
Feb 11, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VX-01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetic Retinopathy
- NPDR - Non Proliferative Diabetic Retinopathy
Approved drugs for the same conditions: Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "VX-01" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01Pivotal-lookingActive, not recruiting
Vantage Biosciences LtdIndustry
NCT06770933 · 100 participants (planned) · Start Feb 11, 2025 · Primary completion Jul 2027
Drug: VX-01; Placebo · For: Diabetic Retinopathy; NPDR - Non Proliferative Diabetic Retinopathy
Sites: Beverly Hills, California; Palo Alto, California; Santa Barbara, California · 27 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Rapid and reliable diagnosis of mucormycosis using colorimetric loop-mediated isothermal amplification.
Gu Y, Ibrahim BA, Gebremariam T, et al. · J Clin Microbiol 2026
- A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response.
Gu Y, Singh S, Alqarihi A, et al. · Sci Transl Med 2025
Also in development for Diabetic Retinopathy
- 4D-1503E10 vg, eyePhase 35 trials
4D Molecular Therapeutics · Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
- TiespectusEYE201, MK-8748Phase 35 trials
EyeBiotech Ltd. · Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization
- Surabgene LomparvovecABBV-RGX-314Phase 32 trials
AbbVie · Diabetic Retinopathy, Neovascular Age-related Macular Degeneration
- TarcocimabTarcocimab tedromer, KSI-301Phase 32 trials
Kodiak Sciences Inc · Wet Age-related Macular Degeneration, Diabetic Retinopathy
- PER-001 Intravitreal ImplantPhase 22 trials
Perfuse Therapeutics, Inc. · Diabetic Retinopathy, Open-angle Glaucoma
- PER-001 Intravitreal Implant - ShamPhase 22 trials
Perfuse Therapeutics, Inc. · Diabetic Retinopathy, Open-angle Glaucoma
- BI 764524Phase 21 trial
Boehringer Ingelheim · Diabetic Retinopathy
- INV-102Phase 21 trial
Invirsa, Inc. · Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.